Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American Thyroid Association
30 September 2021 - 2:06PM
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical
company advancing new treatments for patients suffering from
serious diseases but underserved by today's therapies, announced
today that two posters featuring preclinical data on VRDN-001 and
VRDN-002 are scheduled to be presented at the 90th Annual Meeting
of the American Thyroid Association (ATA), which is being held from
September 30th through October 3rd.
Poster Presentation Details: |
Title: |
VRDN-002, A
Second-Generation Insulin Like Growth Factor-1 Receptor (IGF-1R)
Antagonist Antibody for Thyroid Eye Disease: Preclinical
Pharmacokinetic Profile and Clinical Promise |
Poster: |
#37 |
Poster Session (1): |
Thursday Poster Review Session |
Time and Date: |
Thursday, September 30, 2021, 12:15-1:00 p.m. EDT (Virtual
Poster) |
Poster Session (2): |
Thursday Highlighted Posters Session #3 |
Time and Date: |
Thursday, September 30, 2021, 4:00-5:00 p.m. EDT |
|
|
Title: |
Characterization of VRDN-001, a High Affinity and Potent
anti-IGF-1R Inhibitory Antibody in Development for the Treatment of
Thyroid Eye Disease |
Poster #: |
#187 |
Poster Session: |
Saturday Poster Review Session |
Time and Date: |
Saturday, October 2, 2021, 1:00-2:00 p.m. EDT |
About Viridian Therapeutics,
Inc.
Viridian Therapeutics is a biotechnology company
advancing new treatments for patients suffering from serious
diseases but underserved by today’s therapies. Viridian’s most
advanced program, VRDN-001, is a differentiated monoclonal antibody
targeting insulin-like growth factor-1 receptor (IGF-1R), a
clinically and commercially validated target for the treatment of
thyroid eye disease (TED), a debilitating auto-immune disease that
causes inflammation and fibrosis within the orbit of the eye which
can cause double vision, pain, and potential blindness. Patients
with severe disease often require multiple remedial surgeries to
the orbit, eye muscles and eyelids. Viridian is based in Waltham,
Massachusetts.
Viridian Contacts:
Investors:Dan FerryLifeSci
Advisors617-430-7576IR@viridiantherapeutics.com
Media:Darby PearsonVerge Scientific
Communications703-587-0831PR@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024